- Home
- VTEX vs ORIC Comparison
VTEX vs ORIC Comparison
Compare VTEX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTEX
- ORIC
- Stock Information
- Founded
- VTEX 1999
- ORIC 2014
- Country
- VTEX Cayman Islands
- ORIC United States
- Employees
- VTEX N/A
- ORIC N/A
- Industry
- VTEX Computer Software: Prepackaged Software
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- VTEX Technology
- ORIC Health Care
- Exchange
- VTEX Nasdaq
- ORIC Nasdaq
- Market Cap
- VTEX 1.1B
- ORIC 940.8M
- IPO Year
- VTEX 2021
- ORIC 2020
- Fundamental
- Price
- VTEX $4.05
- ORIC $9.90
- Analyst Decision
- VTEX Buy
- ORIC Strong Buy
- Analyst Count
- VTEX 4
- ORIC 9
- Target Price
- VTEX $8.33
- ORIC $17.25
- AVG Volume (30 Days)
- VTEX 1.4M
- ORIC 1.3M
- Earning Date
- VTEX 08-07-2025
- ORIC 08-12-2025
- Dividend Yield
- VTEX N/A
- ORIC N/A
- EPS Growth
- VTEX 48.79
- ORIC N/A
- EPS
- VTEX 0.05
- ORIC N/A
- Revenue
- VTEX $230,497,000.00
- ORIC N/A
- Revenue This Year
- VTEX $11.98
- ORIC N/A
- Revenue Next Year
- VTEX $16.13
- ORIC N/A
- P/E Ratio
- VTEX $77.68
- ORIC N/A
- Revenue Growth
- VTEX 4.53
- ORIC N/A
- 52 Week Low
- VTEX $3.93
- ORIC $3.90
- 52 Week High
- VTEX $8.03
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- VTEX 20.83
- ORIC 47.41
- Support Level
- VTEX $3.93
- ORIC $9.37
- Resistance Level
- VTEX $4.43
- ORIC $10.06
- Average True Range (ATR)
- VTEX 0.24
- ORIC 0.56
- MACD
- VTEX -0.17
- ORIC -0.07
- Stochastic Oscillator
- VTEX 5.18
- ORIC 39.41
About VTEX VTEX
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.